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M A J O R A R T I C L E
Immunization with the C-Domain of a-Toxin
Prevents Lethal Infection, Localizes Tissue Injury,
and Promotes Host Response to Challenge
with Clostridium perfringens
Dennis L. Stevens,1,4 Richard W. Titball,3 Marie Jepson,3 Clifford R. Bayer,2 Susan M. Hayes-Schroer,2
and Amy E. Bryant1,2
1Veterans Affairs Medical Center, Boise, and 2University of Idaho, Moscow; 3Defence Science and Technology Laboratory, Porton Down, Salisbury,
United Kingdom; 4University of Washington, Seattle
Clostridium perfringens gas gangrene is characterized by rapid tissue destruction, impaired host response, and,
often, death. Phospholipase C (a-toxin) is the virulence factor most responsible for these pathologies. The
present study investigated the efficacy of active immunization with the C-terminal domain of a-toxin (Cpa247–
370) in a murine model of gas gangrene. Primary end points of the study were survival, progression of
infection, and tissue perfusion. Secondary end points, which were based on findings of histologic evaluation
of tissues, included the extent of tissue destruction and microvascular thrombosis, as well as the magnitude
of the tissue inflammatory response. Survival among C-domain–immunized animals was significantly greater
than that among sham-immunized control animals. Furthermore, immunization with the C-domain localized
the infection and prevented ischemia of the feet. Histopathologic findings demonstrated limited muscle ne-
crosis, reduced microvascular thrombosis, and enhanced granulocytic influx in C-domain–immunized mice.
We conclude that immunization with the C-domain of phospholipase C is a viable strategy for the prevention
of morbidity and mortality associated with C. perfringens gas gangrene.
Clostridium perfringens gas gangrene is, without a doubt,
the most fulminant necrotizing infection that affects
humans. The infection can become well established in
traumatized tissues in as little as 6–8 h, and the de-
struction of adjacent healthy muscle can progress sev-
eral inches per hour, despite appropriate antibiotic cov-
erage. Shock and organ failure are present in 50% of
Received 27 August 2003; accepted 5 March 2004; electronically published 19
July 2004.
Presented in part: 4th International Conference on the Molecular Biology and
Pathogenesis of the Clostridia, Woods Hole, Massachusetts, 26–30 April 2003.
Financial support: Office of Research and Development, Medical Research
Service, Department of Veterans Affairs (grant to D.L.S.); Centers of Biomedical
Research Excellence, National Institutes of Health (grant NCRR P20RR15587 to
A.E.B.).
Reprints or correspondence: Dr. Dennis L. Stevens, Infectious Diseases Section,
Veterans Affairs Medical Center, 500 W. Fort St. (Bldg. 45), Boise, ID 83702
(dlsteven@mindspring.com).
The Journal of Infectious Diseases 2004; 190:767–73
 2004 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2004/19004-0015$15.00
infected patients, and, of these patients, 40% die (re-
viewed in [1]). Even with modern medical advances
and intensive care regimens, the centuries-old practice
of radical amputation performed on an emergent basis
remains the single best treatment. Furthermore, unlike
most other soft tissue infections, clostridial myonecro-
sis is also remarkable for both the absence of acute
inflammatory cells in tissues and the accumulation of
leukocytes between fascial planes and within small ves-
sels (leukostasis) near the demarcation between healthy
and necrotic tissues [2–4].
Classic studies have identified a-toxin (a phospholi-
pase C; PLC) and v-toxin (a cholesterol-binding cytoly-
sin) as the principal toxins involved in the pathogenesis
of this infection (reviewed in [1]). More recently, elegant
genetics-based studies have elucidated the structure/
function relationships of both these toxins (reviewed in
[4]). Work from our laboratory has demonstrated that
PLC contributes to the shock associated with gas gan-
grene by directly impairing myocardial contractility [5].
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Furthermore, PLC contributes to the rapid destruction of viable
tissue by altering inflammatory and endothelial cell functions [6,
7], by stimulating microvascular occlusion [8–10], and by in-
hibiting the tissue inflammatory response [11].
Williamson and Titball [12] demonstrated that immuniza-
tion with the C-terminal domain of a-toxin (Cpa247–370) induced
protection against the lethal effect of the toxin and also ensured
the survival of animals challenged with 10 LD100 doses of viable
C. perfringens type A. In the present study, we investigated
whether such protection is accompanied by improvements in
microvascular function and tissue inflammatory responses.
MATERIALS AND METHODS
PLC C-domain. The recombinant carboxy-terminal domain
(i.e., C-domain) used in these studies was produced in Esch-
erichia coli as a glutathione-S-transferase (GST) fusion with aa
247–370 of a-toxin, as described elsewhere [12, 13]. There-
fore, the protein used in our studies was devoid of any other
C. perfringens proteins. The fusion protein was purified and
cleaved from GST by use of factor Xa, and the released C-
domain was purified from the GST before use. The isolated C-
domain appeared as a single band when analyzed by SDS-PAGE
and Coomassie blue staining. Stock C-domain contained 10.2
mg/mL protein that was estimated to be 198% pure.
Animal studies. Animal experiments were approved by
the Animal Subjects Subcommittee, Veterans Affairs Medical
Center (Boise, ID) and adhered to guidelines of the National
Institutes of Health. Female Swiss Webster outbred mice (body
weight, 16–18 g) were actively immunized against the PLC C-
domain over the course of 9 weeks, by successive intraperitoneal
injections of 12.5 mg of C-domain protein in 100 mL of Freund
complete adjuvant (for the first immunization) or 100 mL of
Freund incomplete adjuvant (for booster immunizations), at
3-week intervals, for a total of 3 doses. Sham-immunized an-
imals received an equal volume of adjuvant alone, according
to the same schedule followed for the C-domain–immunized
animals. One week after administration of the last booster im-
munization, 6 animals that were randomly chosen from each
immunization group were anesthetized by halothane inhala-
tion, and a blood specimen (500 mL) was obtained from each
by means of retroorbital puncture. Serum from these specimens
was pooled and was used to verify specific antibody production
by Western blot analysis.
The remaining animals in each immunization group were ran-
domly assigned to either a “survival” group ( ) or a “his-np 30
topathology” group ( ). Animals in the survival group werenp 24
challenged intramuscularly with either , , or7 83.75 10 3.75 10
cfu of viable, washed log-phase C. perfringens organ-93.75 10
isms (ATCC 13124), as described elsewhere [14]. After infection,
the animals were monitored every 2 h for the first 24 h and then
every 12 h, for a total of 7 days. Deaths, as well as signs and
symptoms of local and systemic manifestations of gas gangrene,
such as scruffy appearance, overall activity level, swelling of the
infected limb, blackening of the foot, and use of the infected
limb, were recorded. Animals that survived for the entire 7-day
period were considered to be survivors and, at the conclusion
of the study, were euthanized by administration of halothane
anesthesia, followed by cervical dislocation.
Animals in the histopathology group were similarly chal-
lenged with either or cfu of C. perfringens.8 93.75 10 3.75 10
At 0, 0.5, 1, 2, 4, and 8 h after infection, 2 animals in each group
were killed by means of cervical dislocation. Soft tissues obtained
from the infected leg and the uninfected contralateral limb were
carefully dissected and fixed in 10% neutral buffered formalin.
Tissues were paraffin embedded, sectioned, and stained with he-
matoxylin-eosin at the University of Idaho Caldwell Veterinary
Teaching Center (Caldwell, ID). Tissues were reviewed by one
of the investigators (A.E.B.), who was blinded to the sample’s
origin and who scored the section relative to the extent of tissue
necrosis, the magnitude of inflammatory cell infiltration into the
tissue, and the degree of vessel occlusion.
RESULTS
Immunization studies. Immunization against the C-domain
of C. perfringens a-toxin produced a high titer of antibody
recognizing both the purified C-domain protein fragment and
the intact toxin (figure 1A). In contrast, serum obtained from
animals that received adjuvant alone (i.e., sham-immunized
animals) was devoid of such antibody (figure 1B).
Survival studies. At 18 h after infection, survival of animals
that were immunized against the a-toxin C-domain and were
challenged with , , or cfu of C.7 8 93.75 10 3.75 10 3.75 10
perfringens was 90%, 90%, and 80%, respectively, compared with
survival of 40%, 0%, and 0% for sham-immunized animals (fig-
ure 2, left). These survival percentages did not decrease further
during the remaining 6 days of the study (not shown).
Sham-immunized animals demonstrated an increase in swell-
ing and loss of function of the infected leg, regardless of the
inoculum used to initiate infection (figure 2, middle). Similarly,
animals immunized against the C-domain demonstrated an
increase in swelling and limping after infection. However, these
manifestations were localized, transient, and highly dose de-
pendent in this actively immunized group (figure 2, middle).
Similarly, sham-immunized control animals that were chal-
lenged with the highest inoculum demonstrated a marked
blackening of the foot, which was indicative of an irreversible
loss of tissue perfusion (figure 2 [right] and figure 3). System-
ically, all animals in this group had hematuria. However, for
animals that were immunized against the C-domain and were
similarly challenged, the discoloration of the foot was less in-
tense in color and was transient (figure 2, right), and there was
no evidence of hematuria. In the groups that received lower
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Figure 1. Anti–phospholipase C (PLC) antibody is produced in mice
immunized against the C-domain of PLC, as demonstrated by Western
blots. Lanes 1 and 2, Crude 80% ammonium sulfate precipitate of proteins
from log-phase Clostridium perfringens (ATCC 13124); lane 3, recombinant
C. perfringens v-toxin; lane 4, recombinant C. perfringens PLC; lane 5,
purified C-domain; lane 6, biotinylated molecular weight markers. Blot A
was developed with serum obtained from mice ( ) that were activelynp 6
immunized against the C-domain of C. perfringens PLC, as described in
Materials and Methods. Blot B was developed with serum obtained from
mice that received adjuvant alone.
inocula, alterations in perfusion of the foot were significantly
less marked (figure 2, right).
Histopathologic studies. Sham- or C-domain–immunized
animals were challenged with intramuscular injection of either
or cfu of washed log-phase C. perfringens.8 93.75 10 3.75 10
Two animals in each group were killed, by means of cervical
dislocation, at 0, 0.5, 1, 2, 4, or 8 h after infection, and the
tissues of the animals were processed for routine hematoxylin-
eosin staining. Few morphologic changes were seen among the
tissue samples obtained from animals killed at 0 or 0.5 h after
infection in either immunization group, although the inoculum
was readily visible (data not shown). By 1 h after infection,
focal areas of tissue destruction adjacent to the site of infection
were visible, especially in the sham-immunized group (figure
4A). A marked inflammatory response was observed in tissue
samples obtained from animals immunized against the C-
domain (figure 4B), whereas it was notably absent in samples
obtained from sham-immunized control animals (figure 4A).
Similarly, by 4 h after infection, animals immunized against the
C-domain had more limited tissue destruction, and polymor-
phonuclear leukocytes were still visible within the infected mus-
cle (compare figure 4E and 4F). At 8 h after infection, little
recognizable tissue architecture was discernable at the infection
site in sham-immunized animals, whereas tissues from the C-
domain–immunized animals showed little change from the 4-
h time point (not shown).
Inspection of the vasculature within and adjacent to the site
of infection revealed large occlusive intravascular cellular ag-
gregates in the sham-immunized control animals, at times 2
h after infection (figure 4C). Vessels from C-domain–immu-
nized animals did not show signs of intravascular aggregate
formation (figure 4D), except at 4 h after infection with the
highest inoculum (not shown).
DISCUSSION
Development of a vaccine for gas gangrene due to C. perfringens
has been extensively investigated because the infection has a
high associated mortality rate, causes extensive morbidity, and
often occurs with a high incidence, as exemplified during World
Wars I and II. During the Cold War (1950–1970), studies of
vaccines were justified on the basis of the likelihood that large
numbers of military and civilian casualties would be at risk for
gas gangrene after a nuclear holocaust [15]. The present world
situation portends another possible scenario of mass casualties
of war with extensive injuries conducive to gas gangrene. Thus,
for military personnel, the need still exists to develop novel
strategies to prevent or attenuate the course of C. perfringens
gas gangrene. Such strategies could also be safely used either
for “at-risk” populations, such as elderly individuals or indi-
viduals with diabetes (who may require lower limb surgery as
a result of trauma or poor circulation), or for individuals un-
dergoing intestinal surgery. Lastly, a hyperimmunoglobulin
could also be developed to treat victims of acute traumatic
injury prophylactically and to attenuate the spread of infection
in patients with established gas gangrene.
Several studies have demonstrated that active immunization
with crude toxoid preparations was protective in experimental
infections [15–18]. In addition, the potential efficacy of passive
immunization for the prevention of gas gangrene in humans was
investigated by British physicians during World War II by im-
munization of wounded soldiers with gas gangrene antitoxin, a
serum preparation obtained from horses immunized with a tri-
valent toxoid of crude antigens from C. perfringens, C. septicum,
and C. histolyticum [19]. Although the investigators did not show
that the incidence of gas gangrene was reduced among these
wounded soldiers, they did demonstrate that the incubation time
for gas gangrene was prolonged from 33 h, among 41 soldiers
who did not receive the antitoxin, to 68 h among the 34 soldiers
who did receive the antitoxin [19]. These same investigators
concluded, albeit somewhat anecdotally, that passive immuni-
zation was effective in the treatment of established gas gangrene,
so long as antibiotics and surgery were also implemented.
On the basis of early suspicion that a-toxin was the major
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Figure 2. Female Swiss Webster mice were immunized against the C-domain of Clostridium perfringens phospholipase C, as described in Materials
and Methods. Control animals received adjuvant alone. Animals were challenged with an intramuscular injection, in the right thigh muscle, of either
, , or cfu of washed, log-phase C. perfringens (ATCC 13124). Animals were monitored for survival (A), swelling of the7 8 93.75 10 3.75 10 3.75 10
infected leg (B), and signs of reduced perfusion (blackening) of the foot distal to the infected site (C). The data reflect the percentage of surviving
animals that exhibited these features.
lethal toxin of C. perfringens, strategies began using purified a-
toxin as the primary immunogen. The results of efficacy studies
were varied, causing MacLennan [20] to conclude that it was
impossible to convert C. perfringens alpha toxin to a toxoid
and that any immunizing potency of such preparations resided
in residual undenatured toxin. The difficulty of maintaining
high antigenicity while totally inactivating a-toxin to the extent
that such a preparation would be safe for human immunization
posed insurmountable problems, and, thus, a search for alter-
native vaccines and toxoid preparations became necessary. For
example, Ito [21], using highly purified a-toxin, low concen-
trations of formalin (0.1%), and exogenously added l-lysine,
demonstrated high antigenicity, low toxicity, and protection in
mice that were immunized with this toxoid and were subse-
quently challenged with lethal doses of C. perfringens.
Although little additional work in this area has occurred for
130 years, modern technology offers some novel strategies, in-
cluding gene-based alteration of the amino acid sequence of
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Figure 3. Severe blackening of the foot was observed in sham-immunized
animals challenged with cfu of Clostridium perfringens.93.75 10
a-toxin, truncation of active toxin by a variety of methods,
and use of neutralizing monoclonal antibodies directed against
a-toxin. In previous studies that used this latter approach, we
passively immunized mice with a single dose of neutralizing
monoclonal antibody against a-toxin, followed by challenge
with a 100% lethal dose of log-phase C. perfringens [22]. These
studies demonstrated that the early course of gas gangrene
could be dramatically improved but that all animals subse-
quently developed gas gangrene and died. We concluded that
a greater degree of protection would require repeated doses of
antitoxin because of the shortened half-life and depletion of
specific antibody in the face of continued production of a-
toxin at the site of infection. Thus, active immunization against
a-toxin might provide a nondepletable source of antibody that
would be sufficient to protect animals long enough for the acute
inflammatory reaction to provide innate resistance.
More recent studies have capitalized on the structure/function
attributes of the C. perfringens a-toxin. Specifically, a-toxin has
an N-terminal domain with sequence similarity to PLC enzymes
from other bacteria, as well as a smaller b-sandwich C-terminal
domain that is responsible for calcium-dependent membrane
binding and hemolysis [23]. Both domains are required for tox-
icity. Analysis of the a-toxin structure by x-ray crystallography
has confirmed the 2-domain structure, with the larger a-helical
N-terminal domain containing the active enzymatic site. The C-
terminal C2-like domain has strong structural analogy to eu-
karyotic phospholipid and/or calcium-binding C2 domains, such
as those that have been found in intracellular second-messenger
proteins and human aracidonate 5-lipoxygenase [24]. The ty-
rosine residues of the a-toxin C2-like domain interact with the
calcium/phosphatidylcholine complex of eukaryotic cell mem-
branes, leading to binding of the toxin to the membrane surface
[25] and generation of intracellular messengers, such as diacyl-
glycerol and ceramide [26].
Both of these domains previously have been expressed in E.
coli and have been purified. Immunization of mice with either
of the recombinant domains elicits good antibody responses
that react with the toxin [12]. However, only immunization
with the C-terminal domain provides protection against a sub-
sequent challenge with a-toxin or protection against gas gan-
grene in the murine model of disease [12]. The reasons why
the C-terminal domain is a protective immunogen are not fully
clarified. However, because this domain plays a key role in the
binding of the a-toxin to eukaryotic cell membranes [23, 27,
28], it is possible that antibody against this domain blocks the
initial membrane-binding event. In support of this possibility,
it has been shown that antisera against the C-terminal domain
(but not antisera raised against the amino-terminal domain)
are able to inhibit the hemolytic activity of the toxin [12]. The
epitopes in the C-terminal domain that are responsible for the
induction of neutralizing antibody have not yet been identified.
However, previous studies have shown that immunization with
the recombinant C-terminal domain, derived from C. perfringens
strain ATCC 13124 (a type strain), provides protection against
the a-toxin produced by C. perfringens strain CER89L43, which
was isolated from a diseased calf [29]. Of importance, the C.
perfringens strain CER89L43 and the ATCC 13124 a-toxins show
significant sequence diversity, including diversity in the C-ter-
minal region. This finding suggests that the C-terminal domain
could serve as a vaccine that is protective against a-toxin from
a wide range of C. perfringens isolates.
Using genetic techniques to develop a truncated a-toxin en-
compassing aa 247–370 (Cpa247–370), Williamson and Titball
demonstrated that this protein had no toxicity and that anti-
body directed against this protein neutralized both the phos-
pholipase and hemolytic activities of PLC [12]. Furthermore,
Williamson and Titball [12] demonstrated that active immu-
nization with 3 doses protected mice against lethal challenge
with wild-type C. perfringens.
Results from the present study confirm that active immuni-
zation of mice with the C-domain of a-toxin (Cpa247–370) pro-
vided protection to 80%–90% of mice challenged with 10–100
lethal doses of washed, log-phase C. perfringens. In addition, ac-
tive immunization greatly altered the early histopathologic find-
ings of infection, whereas sham-immunized mice demonstrated
an absence of leukocytic infiltration, accumulation of neutrophil-
platelet aggregates intravascularly, and rapid progression to typ-
ical gas gangrene of the entire extremity. Of interest, at the site
of infection, vaccinated animals had evidence of neutrophil influx
to the site of inoculum as early as 1 h after infection. In addition,
blood vessels adjacent to the inoculum were devoid of leukocyte-
platelet aggregates. At later time points, these histopathologic
differences were striking.
The general appearance of the wound reflected the histo-
pathologic differences in that infection in vaccinated animals
remained localized to the site of inoculation, probably as a result
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Figure 4. Tissue inflammatory response to intramuscular infection with Clostridium perfringens. Animals were actively immunized against the
phospholipase C C-domain, as described in Materials and Methods (B, D, and F). Control animals received adjuvant alone (A, C, and E). At 1 h (A
and B), 2 h (C and D), or 4 h (E and F) after infection with cfu of C. perfringens, tissue from the infected site was harvested and processed83.75 10
for routine hematoxylin-eosin staining. At 1 h after infection, extensive necrosis of tissue was apparent in the sham-immunized animals, a line of
demarcation between healthy and necrotic tissue was visible, and infiltrating polymorphonuclear leukocytes (PMNL) were absent (A). In contrast,
muscle had a relatively good appearance in the C-domain–immunized animals (B), and PMNL influx was clearly visible (solid arrows). Occlusive
intravascular aggregates appeared in the vessels adjacent to the site of infection in tissues obtained from sham-immunized animals (C; white arrow),
whereas vessels in the C-domain–immunized animals remained patent (D). By 4 h after infection, muscle destruction was more widespread in the
sham-immunized animals, and the tissue inflammatory response remained absent (E). In contrast, the skeletal muscle in the C-domain–immunized
animals showed significantly less necrosis, and the PMNL influx was more pronounced than that noted for the sham-immunized animals (F). Solid
arrows denote infiltrating PMNL. I, Bacterial inoculum.
of containment by the acute inflammatory reaction, just as
Staphylococcus aureus infection is contained by neutrophils
leading to a localized abscess and not a progressive necrotizing
lesion. Although some small aggregates were observed in the
blood vessels of vaccinated animals, these aggregates were dra-
matically less apparent than those observed in sham-immu-
nized control animals. That these small aggregates did not lead
to permanent compromise of the microvasculature is confirmed
by our observations that early cyanosis of the foot of the affected
leg was transient and resolved within hours. In sharp contrast,
early cyanosis of the foot in sham-immunized control animals
gradually progressed to cold, blackened feet.
Taken together, results from the present study demonstrate
excellent efficacy of the truncated C-domain of a-toxin as an
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immunogen for vaccination. In addition, these findings support
our hypothesis that a-toxin–induced dysregulation of the im-
mune response of the host fails to contain C. perfringens locally.
Furthermore, a-toxin–induced activation of neutrophils, plate-
lets, and endothelial cells results in the formation of occlusive
intravascular aggregation, such that perfusion decreases dra-
matically and irreversibly in adjacent tissues [9, 10]. To the
host, this represents accelerated ischemic necrosis and loss of
limb. To the anaerobic bacterium, C. perfringens, this pathogen-
ic scenario ensures an ideal hypoxic environment.
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